Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual ...
Durvalumab targets PD-L1, a key immune checkpoint. Normally, antigen-presenting cells (APCs) recognize cancer cell antigens and activate cytotoxic T cells, which travel to the tumor site for ...
Schlesinger: For advanced cSCC, immunotherapy has been a game-changer. The first immunotherapy drugs approved in the space were PD-1 inhibitors such as cemiplimab (Libtayo; Regeneron) and ...
Effect of fusobacterium nucleatum on NF-κB/HIF-1α/CCL20 pathway and M2 macrophages infiltration in esophageal squamous cell carcinoma. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Findings of the BEATcc trial suggest PD-L1 status is not a reliable biomarker for guiding immunotherapy selection in patients with recurrent or metastatic cervical cancer, potentially simplifying ...
A multinational collaboration co-led by the Garvan Institute of Medical Research has uncovered a potential explanation for why some cancer patients receiving a type of immunotherapy called checkpoint ...
TACTI-004 planned ~756 patients across >150 sites and enrolled 378 by February 2026, including squamous and nonsquamous NSCLC irrespective of PD-L1 status. Randomization compared eftilagimod alfa plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results